sepsis

Reading File

Finding Sources

Searching PubMed

"sepsis"[MeSH Terms] AND "guideline"[pt]

Reading File

Sepsis is a large topic. Here's the map of what it covers, a brief overview, and then I'll let you pick where to go deep.

Topic Breakdown

Definitions & Diagnostic Criteria - Sepsis-1/2/3, SIRS vs SOFA/qSOFA, septic shock criteria
Epidemiology - incidence, mortality, cost burden
Pathogens & Sites of Infection - common organisms, community vs hospital onset
Pathophysiology - host response dysregulation, immune/coagulation/endothelial dysfunction
Clinical Presentation & Workup - signs, labs (lactate, cultures), imaging
Management - fluid resuscitation, vasopressors, antibiotics, source control (Surviving Sepsis Campaign bundle)
Complications & Prognosis - organ failure, ARDS, DIC, post-sepsis syndrome, mortality

Brief Overview

Definitions: Sepsis is currently defined (Sepsis-3, 2016) as life-threatening organ dysfunction caused by a dysregulated host response to infection, identified clinically by an increase in SOFA score of ≥2 points. This replaced the older Sepsis-1/2 approach based on SIRS criteria (temp <36°C or >38°C, HR >90, RR >20 or PaCO2 <32, WBC <4,000 or >12,000/μL), which was considered too nonspecific. Septic shock is a subset of sepsis with persistent hypotension requiring vasopressors to maintain MAP ≥65 mmHg despite adequate fluid resuscitation, plus elevated lactate - mortality runs around 40% (Washington Manual of Medical Therapeutics, p. 295; Harrison's Principles of Internal Medicine, 22E).

Burden: Globally about 48.9 million sepsis cases and 11 million deaths occur each year (roughly 1 in 5 global deaths), with 85% of deaths in low- and middle-income countries. In the US, sepsis affects ~6% of hospitalized adults, causes ~350,000 deaths/discharges to hospice annually, and costs over $13 billion/year in inpatient care (Harrison's Principles of Internal Medicine, 22E, p. 315).

Pathogens: About 88% of cases are community-onset. Roughly half of culture-positive cases are gram-positive (S. aureus, Streptococcus, Enterococcus) with the rest gram-negative (E. coli, Klebsiella, etc.), with meaningful rates of antibiotic resistance (MRSA, VRE) (Harrison's Principles of Internal Medicine, 22E, p. 315).

Management core (Surviving Sepsis Campaign approach): early IV crystalloid resuscitation (≥30 mL/kg in the first hour, adjusted for volume responsiveness and heart failure risk), norepinephrine as first-line vasopressor (preferred over dopamine due to fewer adverse events, with vasopressin as a common second-line add-on), prompt blood cultures followed immediately by broad-spectrum antibiotics, and source control (e.g., draining an abscess or debriding infected tissue) as soon as feasible. Balanced crystalloids (lactated Ringer's) may have an edge over normal saline in reducing renal dysfunction (Washington Manual of Medical Therapeutics, p. 295-296).

A note on evidence currency: a 2025 systematic review using the AGREE II instrument critically appraised the quality of current infection-management guidelines in sepsis (PMID: 39984828), and a 2024 systematic review looked "beyond" the Surviving Sepsis Campaign at interventions affecting mortality (PMID: 38093626) - both suggest active ongoing refinement of sepsis guidelines, so if you want current bundle specifics I can pull details from these.

Which topic would you like me to go deep on?

Asking for Preferences

Which sepsis topic should I go deep on?

Sepsis is a large topic. Here's the map of what it covers, a brief overview, and then I'll let you pick where to go deep.

Topic Breakdown

Definitions & Diagnostic Criteria - Sepsis-1/2/3, SIRS vs SOFA/qSOFA, septic shock criteria
Epidemiology - incidence, mortality, cost burden
Pathogens & Sites of Infection - common organisms, community vs hospital onset
Pathophysiology - host response dysregulation, immune/coagulation/endothelial dysfunction
Clinical Presentation & Workup - signs, labs (lactate, cultures), imaging
Management - fluid resuscitation, vasopressors, antibiotics, source control (Surviving Sepsis Campaign bundle)
Complications & Prognosis - organ failure, ARDS, DIC, post-sepsis syndrome, mortality

Brief Overview

Definitions: Sepsis is currently defined (Sepsis-3, 2016) as life-threatening organ dysfunction caused by a dysregulated host response to infection, identified clinically by an increase in SOFA score of ≥2 points. This replaced the older Sepsis-1/2 approach based on SIRS criteria (temp <36°C or >38°C, HR >90, RR >20 or PaCO2 <32, WBC <4,000 or >12,000/μL), which was considered too nonspecific. Septic shock is a subset of sepsis with persistent hypotension requiring vasopressors to maintain MAP ≥65 mmHg despite adequate fluid resuscitation, plus elevated lactate - mortality runs around 40% (Washington Manual of Medical Therapeutics, p. 295; Harrison's Principles of Internal Medicine, 22E).

Burden: Globally about 48.9 million sepsis cases and 11 million deaths occur each year (roughly 1 in 5 global deaths), with 85% of deaths in low- and middle-income countries. In the US, sepsis affects ~6% of hospitalized adults, causes ~350,000 deaths/discharges to hospice annually, and costs over $13 billion/year in inpatient care (Harrison's Principles of Internal Medicine, 22E, p. 315).

Pathogens: About 88% of cases are community-onset. Roughly half of culture-positive cases are gram-positive (S. aureus, Streptococcus, Enterococcus) with the rest gram-negative (E. coli, Klebsiella, etc.), with meaningful rates of antibiotic resistance (MRSA, VRE) (Harrison's Principles of Internal Medicine, 22E, p. 315).

Management core (Surviving Sepsis Campaign approach): early IV crystalloid resuscitation (≥30 mL/kg in the first hour, adjusted for volume responsiveness and heart failure risk), norepinephrine as first-line vasopressor (preferred over dopamine due to fewer adverse events, with vasopressin as a common second-line add-on), prompt blood cultures followed immediately by broad-spectrum antibiotics, and source control (e.g., draining an abscess or debriding infected tissue) as soon as feasible. Balanced crystalloids (lactated Ringer's) may have an edge over normal saline in reducing renal dysfunction (Washington Manual of Medical Therapeutics, p. 295-296).

A note on evidence currency: a 2025 systematic review using the AGREE II instrument critically appraised the quality of current infection-management guidelines in sepsis (PMID: 39984828), and a 2024 systematic review looked "beyond" the Surviving Sepsis Campaign at interventions affecting mortality (PMID: 38093626) - both suggest active ongoing refinement of sepsis guidelines, so if you want current bundle specifics I can pull details from these.

Which topic would you like me to go deep on?

all of it i have a pt of sepsis what to see how to manage and evaluate

Finding Sources

Reading File

Sepsis: Bedside Evaluation and Management

1. Recognize and Confirm the Diagnosis

Definition (Sepsis-3): Sepsis = life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalized as an acute rise in SOFA score of ≥2 points in a patient with suspected/confirmed infection (Harrison's Principles of Internal Medicine, 22E; Barash Clinical Anesthesia, 9e).

Quick screen at the bedside - qSOFA (any 2 of 3 suggests high risk, prompts full workup):

Systolic BP ≤100 mmHg
Respiratory rate ≥22/min
Altered mentation (GCS <15)

qSOFA is a rapid screening/prognostic tool, not a diagnostic replacement for full SOFA (Harrison's Principles of Internal Medicine, 22E, "Evaluation of the Patient with Shock").

Full SOFA score (used to confirm organ dysfunction, ideally in ICU/monitored setting) - 6 systems scored 0-4:

Respiratory: PaO2/FiO2 ratio
Coagulation: platelet count
Liver: bilirubin
Cardiovascular: MAP / vasopressor requirement
CNS: Glasgow Coma Scale
Renal: creatinine / urine output

Septic shock = sepsis + persistent hypotension requiring vasopressors to keep MAP ≥65 mmHg despite adequate fluid resuscitation, usually with lactate >2 mmol/L. Mortality ~40% (Washington Manual of Medical Therapeutics, p. 295).

2. Evaluation / Workup

History and exam: hunt for a source - lungs, urinary tract, abdomen, skin/soft tissue, catheters/lines, recent procedures.
Labs: CBC with differential (leukocytosis or bandemia is supportive but nonspecific), CMP (creatinine/renal function, LFTs, bilirubin - a rise signals organ dysfunction), coagulation panel (PT/aPTT, fibrinogen, platelets - screen for DIC), lactate (a core prognostic marker - mortality roughly tracks 5% at <2.5 mg/dL, 9% at 2.5-4, 28% at >4 mg/dL), venous/arterial blood gas, procalcitonin/CRP if useful locally for antibiotic stewardship.
Cultures: blood cultures x2 (from different sites) plus cultures from any suspected source (urine, sputum, wound, line tips) before antibiotics if this doesn't meaningfully delay treatment.
Imaging: guided by suspected source - chest x-ray, abdominal/pelvic CT, ultrasound for abscess/collection, echo if endocarditis or cardiogenic component suspected.
Rule out mimics/other shock types: hypovolemic (bleeding, dehydration), cardiogenic (MI, tamponade), obstructive (PE, tension pneumothorax), anaphylactic - all can look similar hemodynamically (ROSEN's Emergency Medicine).

(Source-specific reference for detail: ROSEN's Emergency Medicine, Concepts and Clinical Practice - "Septic Shock" chapter, laboratory testing section.)

3. Management - Surviving Sepsis Campaign "Hour-1 Bundle"

Act on these simultaneously, not sequentially, within the first hour of recognition:

Measure lactate; remeasure if initial lactate >2 mmol/L to track resuscitation response.
Obtain blood cultures before giving antibiotics (don't delay antibiotics more than ~45 min to do this).
Start broad-spectrum antibiotics empirically, targeted at the likely source, then narrow once cultures return. Delay is directly associated with increased mortality (Washington Manual of Medical Therapeutics, p. 295-296).
Fluid resuscitation: ≥30 mL/kg (ideal body weight) IV crystalloid within the first hour for hypotension or lactate ≥4 mmol/L. Prefer balanced crystalloids (e.g., lactated Ringer's) over normal saline - associated with less renal dysfunction and possibly lower mortality. Reduce/titrate if the patient has heart failure or is showing volume overload; give more if still fluid-responsive.
Vasopressors if MAP stays <65 mmHg despite adequate fluids: norepinephrine is first-line (fewer arrhythmias/adverse events than dopamine); vasopressin commonly added as a second agent to reduce norepinephrine dose. Epinephrine or others as clinically indicated.
Source control: identify and address the anatomical source as soon as reasonably possible - drain an abscess, remove/exchange an infected line, debride necrotizing soft tissue infection, relieve obstruction (e.g., ureteral stent for obstructive pyelonephritis).

4. Ongoing Monitoring

Reassess volume responsiveness serially (dynamic measures - passive leg raise, pulse pressure variation, bedside ultrasound - rather than static CVP) to avoid fluid overload.
Trend lactate clearance.
Track SOFA components daily to follow organ dysfunction trajectory.
Watch for complications: ARDS, AKI, DIC, ileus/GI dysfunction, delirium, and critical illness myopathy/post-sepsis syndrome in survivors.
De-escalate antibiotics once culture/sensitivity data return; reassess need for continued vasopressors as MAP stabilizes and lactate clears.

Evidence currency note

Two recent systematic reviews are worth knowing about: a 2025 AGREE II critical appraisal of sepsis infection-management guideline quality (PMID: 39984828) and a 2024 systematic review looking "beyond" the Surviving Sepsis Campaign at mortality-affecting interventions (PMID: 38093626). Both indicate the evidence base and bundle specifics are actively being refined, so if this patient has any complexity (immunocompromised, pregnant, pediatric, renal/hepatic impairment), it's worth double-checking current dosing/threshold specifics against your institution's latest protocol rather than relying solely on textbook figures above.

If you can share more about this specific patient (age, source of infection, comorbidities, current vitals/labs), I can help tailor the antibiotic choice, fluid strategy, or vasopressor titration to their exact situation.